WO2010013141A3 - Substantially pure rosiglitazone hydrogen sulfate - Google Patents
Substantially pure rosiglitazone hydrogen sulfate Download PDFInfo
- Publication number
- WO2010013141A3 WO2010013141A3 PCT/IB2009/006732 IB2009006732W WO2010013141A3 WO 2010013141 A3 WO2010013141 A3 WO 2010013141A3 IB 2009006732 W IB2009006732 W IB 2009006732W WO 2010013141 A3 WO2010013141 A3 WO 2010013141A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogen sulfate
- rosiglitazone
- oxide
- substantially pure
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Provided herein are impurities of rosiglitazone hydrogen sulfate, 4-[2-(N-methyl-2-(N- pyridinyl)amino)ethoxy]bromobenzene (bromo impurity) and 5-[[4-[2-[methyl-(2-pyridinyl- N-oxide)amino]ethoxy]phenyl]methyl]-2,4-thiazolidinedione (N-oxide impurity), and processes for preparing and isolating thereof. Provided further herein is a highly pure rosiglitazone hydrogen sulfate substantially free of bromo and N-oxide impurities, process for the preparation thereof, and pharmaceutical compositions comprising highly pure rosiglitazone hydrogen sulfate substantially free of bromo and N-oxide impurities.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1848/CHE/2008 | 2008-08-01 | ||
IN1848CH2008 | 2008-08-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010013141A2 WO2010013141A2 (en) | 2010-02-04 |
WO2010013141A3 true WO2010013141A3 (en) | 2010-06-17 |
Family
ID=41479616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/006732 WO2010013141A2 (en) | 2008-08-01 | 2009-07-31 | Substantially pure rosiglitazone hydrogen sulfate |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010013141A2 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5741803A (en) * | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
EP1854794A1 (en) * | 2006-05-09 | 2007-11-14 | Teva Pharmaceutical Industries Ltd. | 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
US20070265312A1 (en) * | 2006-05-09 | 2007-11-15 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
WO2007130064A1 (en) * | 2006-05-09 | 2007-11-15 | Teva Pharmaceutical Industries, Ltd. | 2-n-(5-[[4-(2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
US20070293546A1 (en) * | 2006-06-15 | 2007-12-20 | Srinivasula Reddy Maddula | Preparation of rosiglitazone and its salts |
-
2009
- 2009-07-31 WO PCT/IB2009/006732 patent/WO2010013141A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5741803A (en) * | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
EP1854794A1 (en) * | 2006-05-09 | 2007-11-14 | Teva Pharmaceutical Industries Ltd. | 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
US20070265312A1 (en) * | 2006-05-09 | 2007-11-15 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
WO2007130064A1 (en) * | 2006-05-09 | 2007-11-15 | Teva Pharmaceutical Industries, Ltd. | 2-n-(5-[[4-(2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
US20070293546A1 (en) * | 2006-06-15 | 2007-12-20 | Srinivasula Reddy Maddula | Preparation of rosiglitazone and its salts |
Also Published As
Publication number | Publication date |
---|---|
WO2010013141A2 (en) | 2010-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011141933A3 (en) | Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts | |
WO2005080358A3 (en) | Rosiglitazone phosphate and polymorphic forms | |
TN2012000557A1 (en) | Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide | |
HK1203959A1 (en) | Method for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl -2h-phthalazin-1-one 1-()-4-[5-[(34--4--1-) -2- | |
CL2008002142A1 (en) | Compounds derived from 2-amino-6 - ({[2- (4-chlorophenyl) -1,3-thiazol-4-yl] methyl} thio) -4- [4- (2-hydroxyethoxy) phenyl] pyridin-3 , 5-dicarbonitrile; preparation procedure; Pharmaceutical composition and use in cardiovascular diseases. | |
WO2008104847A3 (en) | Processes for the preparation of pramipexole and salts thereof | |
PL384446A1 (en) | Salt of 5-[[4-[2-(methyl-2-pyridinamino)ethoxy]phenyl]methyl]-2,4-tiazolidynodion with malonic acid and its production method | |
MX2009009344A (en) | Solid forms of a raf kinase inhibitor. | |
WO2010013141A3 (en) | Substantially pure rosiglitazone hydrogen sulfate | |
WO2009021943A3 (en) | Novel preparation process | |
IL199822A0 (en) | Sealed package of pharmaceutical composition comprising 2-n-(5-[[4-(2-methyl-2-pyridinylamino)ethoxy] phenyl] methyl]-2,4-thiazolidinedione)butanedioic acid, methods of preparation and compositions with rosiglitazone maleate | |
ZA200807190B (en) | Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process | |
TW200833323A (en) | Prophylactic or therapeutic agent for alopecia | |
IL219282A0 (en) | Process for production of 3 - [5 - [4 - (cyclopentyloxy) - 2 - hydroxybenzoyl] - 2 - [(3 - oxo - 2 - substituted - 2, 3 - dihydro - 1, 2- benzisoxazol - 6 - yl) methoxy]phenyl] propionate ester and intermediate for the process | |
HU0600347D0 (en) | Process for the preparation of {2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one (ziprasidon) | |
WO2008062244A8 (en) | Polymorphs of 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrobromide and processes for preparation thereof | |
CY2200159T2 (en) | 2-N-{5-[[4-[2-METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-2-4-THIAZOLIDINODIONE} BUTANIODIOIC ACID, PREPARATION METHODS AND COMPOSITIONS WITH ROSIGLITAZONE MELEINE | |
WO2005073227A3 (en) | A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate | |
WO2008010089A3 (en) | Process for preparation of intermediates of rosiglitazone, rosiglitazone and polymorphic forms thereof | |
DE602005008076D1 (en) | PROCESS FOR THE PREPARATION OF ROSIGLITAZONE | |
HK1057751A1 (en) | A thiazolidinedione derivative and its use as antidiabetic | |
PL385697A1 (en) | Salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione with 1, 5 naphtalene disulfonic acid, and method of its manufacturing | |
WO2008007390A3 (en) | An improved process for purification of zolmitriptan | |
PL380178A1 (en) | Method for the manufacture of 2-[(2, 3, 4-trihydroxiphenyl) methyl) hydrazide D , L-serine hydrochloride | |
WO2008152653A3 (en) | An improved process for the preparation of tamsulosin hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09786209 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09786209 Country of ref document: EP Kind code of ref document: A2 |